5,11-Diketoindenoisoquinoline

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 5,11-Diketoindenoisoquinoline
• 英文别名: 6H-indeno[1,2-h]isoquinoline-5,11-dione
• 化学式: C₁₆H₉NO₂
• 分子量: 247.25
• InChiKey: QMMDOKHBVXTDBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• CUL4B as predictive biomarker for cancer treatment
  申请人：CORNELL UNIVERSITY

  公开号：US10106853B2

  公开（公告）日：2018-10-23

  The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA and protein levels in the subject. The disclosure identifies CUL4B as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents. The current disclosure also identifies novel therapeutic agents that modulate the level of CUL4B expression, and sensitize a subject to treatment with a second therapeutic agent.

  目前公开的内容描述了根据受试者体内的 Cullin 4B 基因、RNA 和蛋白质水平，确定可从 DNA 拓扑异构酶 1 抑制剂治疗中获益的受试者的材料和方法。本公开将 CUL4B 鉴定为癌症诊断和随后使用定向治疗剂治疗的预测性生物标志物。本公开还确定了可调节 CUL4B 表达水平的新型治疗剂，并使受试者对第二种治疗剂的治疗敏感。
• CUL4B AS PREDICTIVE BIOMARKER FOR CANCER TREATMENT
  申请人：CORNELL UNIVERSITY

  公开号：US20150119446A1

  公开（公告）日：2015-04-30

  The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA and protein levels in the subject. The disclosure identifies CUL4B as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents. The current disclosure also identifies novel therapeutic agents that modulate the level of CUL4B expression, and sensitize a subject to treatment with a second therapeutic agent.
• [EN] CUL4B AS PREDICTIVE BIOMARKER FOR CANCER TREATMENT<br/>[FR] CUL4B EN TANT QUE BIOMARQUEUR DE PRÉDICTION POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CORNELL

  公开号：WO2013166366A1

  公开（公告）日：2013-11-07

  The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA and protein levels in the subject. The disclosure identifies CUL4B as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents. The current disclosure also identifies novel therapeutic agents that modulate the level of CUL4B expression, and sensitize a subject to treatment with a second therapeutic agent.